Antibiotic-lock technique with Taurolidine for prevention of central venous catheter infection in neutropenic patients

ISRCTN ISRCTN47102251
DOI https://doi.org/10.1186/ISRCTN47102251
Secondary identifying numbers PI13/01474
Submission date
09/09/2015
Registration date
21/10/2015
Last edited
25/02/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
A central venous catheter (CVC) is a long, thin tube that is inserted into the major vein in the neck (jugular vein), chest (subclavian vein or axillary vein) or groin (femoral vein). CVC’s are considered to be one of the best ways to give long-term medicine treatment, such as chemotherapy. The use of CVC’s has increased considerably in recent years and catheter-related bloodstream infections (CR-BSI) have become a recurrent complication. These infections can cause seriously ill patients with CVC’s to become even more ill or even die. A good way of preventing these infections is by “flushing” the tube with an antibacterial solution, which helps to create a barrier at the catheter site so that harmful bacteria cannot get into the blood (catheter lock solution). This is especially important for patients who have low levels of certain white blood cells in their blood (neutropenia), and are therefore more susceptible to infections. Taurolidine-citrate is an antibiotic which has been shown to be very effective in fighting CR-BSI’s when used as a catheter lock solution. The aim of this study is to see whether using a Tautolidine-lock solution is an effective way of preventing CR-BSI’s in neutropenic patients.

Who can participate?
Adults in hospital, who have a central venous catheter and are likely to develop neutropenia lasting for more than one week.

What does the study involve?
Participants are randomly allocated into one of two groups. The first group (intervention group) is given a 2.5ml solution of 2% Taurolidine-citrate three times a week, and the second group (control group) is given heparin (acting as a placebo as it has no effect on the infection) three times a week. The solution is left in place for one hour (antibiotic-lock technique) for one hour, before it is aspirated (sucked away) with a syringe. Treatment continues until patient recovers from neutropenia; when the catheter needs to be used for continuous medicine treatment; or when the patient dies. Levels of infection at the catheter site or in the blood, throughout the study.

What are the possible benefits and risks of participating?
There are no benefits or risks of participating in this trial.

Where is the study run from?
1. Hospital Universitari de Bellvitge (Spain)
2. Duran i Reynals Hospital – Catalan Institute of Oncology (Spain)

When is the study starting and how long is it expected to run for?
January 2013 to September 2018

Who is funding the study?
The Carlos III Health Institute (Spain)

Who is the main contact?
Dr Carlota Gudiol

Contact information

Dr Carlota Gudiol
Scientific

Infectious Disease Department
Hospital Universitari de Bellvitge
Feixa Llarga s/n
Hospitalet de Llobregat
Bracelona
08907
Spain

Study information

Study designRandomised double-blind placebo-controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleAntibiotic-lock technique with Taurolidine for prevention of central venous catheter infection in neutropenic patients: a randomized, double-blind, placebo-controlled study
Study acronymTAURCAT
Study objectivesAntibiotic-lock technique with Taurolidine would be effective and safe in preventing the bacterial colonization of the central venous catheters in neutropenic patients.
Ethics approval(s)Ethics Committee of the Hospital Universitari de Bellvitge (Comité Ètic d'Investigació Clínica), 06/06/2013, ref: AC019/13
Health condition(s) or problem(s) studied1. Catheter infection
2. Catheter-related bacteremia
InterventionPatients will be randomly assigned to undergo antibiotic-lock technique of the central venous catheter with Taurolidine 3 times a week or with heparin (placebo), during the neutropenic phase. The antibiotic-lock technique of the catheters in both arms will be stopped when the neutrophil count recovers above 500 micro-liters, when the catheter needs to be removed for any reason, when an episode of catheter-related bacteremia occurs, when the catheter needs to be used with a continuous infusion or when the patient dies.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Taurolidine
Primary outcome measureBacterial colonization of at least one of the three hubs of the central venous catheter, measured by the detection of bacterial growth in the hubs, which are cultured 3 times a week, until the end of the intervention.
Secondary outcome measures1. Incidence of catheter-related bacteraemia, measured daily throughout the intervention, using blood cultures when the patient has fever
2. The number of cases where the venous catheter has to be removed for any reason, monitored throughout the intervention period
3. Overall mortality is measured during the intervention period and for 30 days after the end of the intervention in both treatment groups
Overall study start date01/01/2013
Completion date19/05/2018

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants150
Total final enrolment150
Key inclusion criteria1. Adult patients aged > 18 years
2. Hospitalized with leukemia, lymphoma or stem cell transplantation
3. Carry a central venous catheter
4. Likely to develop neutropenia (<500 neutrophils per ul) lasting more than one week
Key exclusion criteria1. Patients with a (not flexible) semi-rigid central venous catheter
2. Patients who have been found to have a positive culture of the hubs or the insertion site of the catheter, previously to randomization
3. Patients in whom the central venous catheter is used for parenteral nutrition or medication that needs continuous infusion
4. Patients receiving systemic antibiotic treatment ≥ 48 hours
5. Patients who have an active infection at the baseline statement
Date of first enrolment15/10/2013
Date of final enrolment19/04/2018

Locations

Countries of recruitment

  • Spain

Study participating centres

Hospital Universitari de Bellvitge
Feixa Llarga
L'Hospitalet de Llobregat
Barcelona
08907
Spain
Duran i Reynals Hospital – Catalan Institute of Oncology
Gran Via 199-203
L'Hospitalet de Llobregat
Barcelona
08908
Spain

Sponsor information

The Carlos III Health Institute (Instituto de Salud Carlos III)
Research organisation

Sinesio Delagado 4
Madrid
28029
Spain

Phone + 34 (0)91 822 20 00
Email oficina.informacion@isciii.es
Website http://www.isciii.es
ROR logo "ROR" https://ror.org/00ca2c886

Funders

Funder type

Hospital/treatment centre

Instituto de Salud Carlos III
Government organisation / National government
Alternative name(s)
SaludISCIII, InstitutodeSaludCarlosIII, Instituto de Salud Carlos III | Madrid, Spain, Carlos III Institute of Health, Institute of Health Carlos III, Carlos III Health Institute, ISCIII
Location
Spain

Results and Publications

Intention to publish date31/12/2019
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planAuthors of the study will try to publish the results of the trial in a high impact factor scientific journal.
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 02/05/2018 Yes No
Results article results 27/01/2020 25/02/2021 Yes No

Editorial Notes

25/02/2021: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.
14/11/2019: The intention to publish date has been changed from 19/05/2019 to 31/12/2019.
07/06/2018: The following changes have been made to the trial record:
1. The overall trial end date was changed from 30/09/2018 to 19/05/2018
2. The intention to publish date was changed from 31/12/2018 to 19/05/2019
11/05/2018: The recruitment end date was changed from 30/06/2018 to 19/04/2018.
04/05/2018: Publication reference added.
15/03/2018: The following updates were made:
1. Recruitment end date was changed from 31/12/2016 to 30/06/2018.
2. Overall trial end date was changed from 31/12/2017 to 30/09/2018.